Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,909 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Event Clear all
Recruiting No phase listed Observational

Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies

NCT04888338
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Data Capture, Electronic Medical Record
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 7:09 PM EDT
Completed No phase listed Observational

Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab

NCT00875238
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
Interventions
trastuzumab, doxorubicin hydrochloride, polymorphism analysis, laboratory biomarker analysis, questionnaire administration, assessment of therapy complications, magnetic resonance imaging
Biological · Drug · Genetic + 2 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 30, 2026, 7:09 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

NCT03297463
View directory record Official record
Conditions
Metastatic Melanoma, Pulmonary Metastases, Hepatic Metastases, Brain Metastases
Interventions
Interleukin-2 & Ipilimumab (P-Ib), Interleukin-2 & Ipilimumab (P-II)
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 30, 2026, 7:09 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy of the EarPopper Device in Children With Recurrent Otitis Media

NCT03534219
View directory record Official record
Conditions
Recurrent Acute Otitis Media, Acute Otitis Media
Interventions
EarPopper
Device
Lead sponsor
Northwell Health
Other
Eligibility
4 Years to 11 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 30, 2026, 7:09 PM EDT
Withdrawn No phase listed Observational

MACE CDS Software Master Enrollment Protocol

NCT06257628
View directory record Official record
Conditions
Cardiac Events
Interventions
Index Event
Device
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
23 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Baltimore, Maryland • Detroit, Michigan • Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 30, 2026, 7:09 PM EDT
Not listed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

NCT00262067
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Bevacizumab, Placebo, Chemotherapy
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
5
States / cities
Fullerton, California • Santa Barbara, California • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 30, 2026, 7:09 PM EDT
Recruiting Not applicable Interventional

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

NCT07225309
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer, Thyroid Cancer, Breast Cancer Stage III, Breast Cancer Stage IV, Prostate Cancer Stage III, Prostate Cancer Stage IV, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Thyroid Cancer Stage III, Thyroid Cancer Stage IV
Interventions
Meaning-Centered Psychotherapy for Latinos /MCP-L
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 7:09 PM EDT
Recruiting Phase 1 Interventional

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

NCT04412616
View directory record Official record
Conditions
Advanced EGFR Positive Solid Tumor
Interventions
ZZ06
Biological
Lead sponsor
Changchun Intellicrown Pharmaceutical Co. LTD
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Fairway, Kansas • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 30, 2026, 7:09 PM EDT
Enrolling by invitation No phase listed Observational

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

NCT02315599
View directory record Official record
Conditions
Pediatric Cancers, Hematologic Malignancies, Solid Tumors
Interventions
anti-CD19 CAR
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 7:09 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, c-MET
Interventions
Telisotuzumab Adizutecan, Standard of Care, Osimertinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 7:09 PM EDT
Completed Phase 3 Interventional

Raloxifene Use for The Heart

NCT00190593
View directory record Official record
Conditions
Cardiovascular Diseases, Breast Neoplasms
Interventions
raloxifene, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older · Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 30, 2026, 7:09 PM EDT
Completed No phase listed Observational

Long-term Effects of COVID-19

NCT05220514
View directory record Official record
Conditions
COVID-19, SAR-CoV-2
Interventions
(R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195), 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 30, 2026, 7:09 PM EDT
Completed Not applicable Interventional

Temporal Window and Episodic Future Thinking in CUD

NCT05507814
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Episodic Future Thinking (EFT), Control Episodic Thinking
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 30, 2026, 7:09 PM EDT
Completed Phase 4 Interventional Results available

D-Cycloserine Enhancement of Exposure in Social Phobia

NCT00633984
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Cognitive Behavioral Group Therapy (CBGT), D-Cycloserine, Placebo
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 30, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Results available

Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery

NCT03212365
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus, Reconstructive Surgery
Interventions
Fixed dose, Variable dose
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 30, 2026, 7:09 PM EDT
Not yet recruiting Not applicable Interventional

High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 Years

NCT07803692
View directory record Official record
Conditions
Idiopathic Generalized Epilepsy
Interventions
Intervention 1, Intervention 2
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 7:09 PM EDT
Recruiting Not applicable Interventional

A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

NCT06693687
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Metastatic Cancer
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 30, 2026, 7:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 7:09 PM EDT
Completed No phase listed Observational

Coronary Heart Disease Incidence: Depression & Inflammation Risk

NCT00241774
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease, Heart Diseases, Depression, Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
3,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 30, 2026, 7:09 PM EDT
Completed No phase listed Observational

Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring

NCT03064360
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
Laboratory Biomarker Analysis, Patient Activity, Questionnaires
Other · Device · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 105 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 30, 2026, 7:09 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

NCT02876835
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
161
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 30, 2026, 7:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multisensory Processing of Alcohol Cues in Young Adult Binge Drinkers

NCT06885190
View directory record Official record
Conditions
Drinking, Binge
Interventions
Presentation of alcohol-related and neutral stimuli
Other
Lead sponsor
Rochester Institute of Technology
Other
Eligibility
18 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 7:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eliminate Risk of Cardiac Surgical Site Events

NCT01425697
View directory record Official record
Conditions
Surgical Site Infections
Interventions
2% Chlorhexidine Gluconate cloths, Standard of Care preoperative preparation.
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
4
States / cities
Lexington, Kentucky • Ridgewood, New Jersey • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 30, 2026, 7:09 PM EDT
Terminated No phase listed Observational

Heart Failure and Risk of Re-Admissions Determined by Abnormal REVEAL Parameters

NCT01357408
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 30, 2026, 7:09 PM EDT